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Introduction: Although cost−utility models are often used to estimate the value of treatments for 
metastatic cancer, limited information is available on the utility of common treatment modalities. 
Bisphosphonate treatment for bone metastases is frequently administered via intravenous infu-
sion, while a newer treatment is administered as a subcutaneous injection. This study estimated 
the impact of these treatment modalities on health state preference.
Methods: Participants from the UK general population completed time trade-off interviews 
to assess the utility of health state vignettes. Respondents first rated a health state representing 
cancer with bone metastases. Subsequent health states added descriptions of treatment modalities 
(ie, injection or infusion) to this basic health state. The two treatment modalities were presented 
with and without chemotherapy, and infusion characteristics were varied by duration (30 minutes 
or 2 hours) and renal monitoring.
Results: A total of 121 participants completed the interviews (52.1% female, 76.9% white). 
Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1 = full 
health; 0 = dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities 
of −0.004, −0.02, and −0.04, respectively. The mean disutility of the 30-minute infusion was 
greater with renal monitoring than without. Chemotherapy was associated with substantial 
disutility (−0.17). When added to health states with chemotherapy, the mean disutilities of injec-
tion, 30-minute infusion, and 2-hour infusion were −0.02, −0.03, and −0.04, respectively. The 
disutility associated with injection was significantly lower than the disutility of the 30-minute 
and 2-hour infusions (P , 0.05), regardless of chemotherapy status.
Conclusion: Respondents perceived an inconvenience with each type of treatment modality, 
but injections were preferred over infusions. The resulting utilities may be used in cost−utility 
models examining the value of treatments for the prevention of skeletal-related events in patients 
with bone metastases.
Keywords: skeletal-related event, infusion, injection
Introduction
When solid tumors metastasize to bone, localized bone destruction occurs, which may 
result in pain, decreased survival, and complications referred to as skeletal-related 
events (SREs).1,2 These SREs, such as pathological fracture, radiation to the bone, 
surgery to the bone, and spinal cord compression, can be severely debilitating, with 
the potential to cause increased pain and functional impairment.3,4 Intravenous (IV) 
bisphosphonates, such as zoledronic acid, have commonly been used for the treatment 
of patients with bone metastases. The bisphosphonates are bone antiresorptive drugs 
that reduce osteoclast activity, thus helping to prevent or delay the onset of SREs.5−7 
Zoledronic acid is administered via IV infusion every 3 to 4 weeks and requires renal 
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monitoring, with dose adjustment if renal impairment is pres-
ent.8 Denosumab, which has a targeted mechanism of action 
distinct from that of bisphosphonates, is a more recently 
developed bone-modifying agent that is also used to prevent 
or delay SREs.9,10 This newer treatment is a fully human 
monoclonal antibody against RANK Ligand (RANKL), a key 
mediator of cancer-induced bone destruction. Denosumab 
is administered via subcutaneous (SC) injection every 4 
weeks, and it does not require renal monitoring.11 In clinical 
trials among patients with solid tumors and bone metastases, 
denosumab has been found to have superior efficacy for the 
prevention of SREs compared with zoledronic acid.10,12,13
As new treatments such as denosumab are developed, 
it is important to evaluate their cost−effectiveness relative 
to existing treatments in order to demonstrate their value to 
patients, clinicians, reimbursement authorities, and payers. 
A cost−utility analysis is a type of cost−effectiveness analysis 
that incorporates the preferences of individuals for different 
treatment-related outcomes. These preferences are quantified 
in terms of utilities, which are values representing health 
status and health-related quality of life (HRQL) on a scale 
with anchors of 0 representing death and 1 representing full 
health. Utilities are most often used to represent preferences 
for health states involving medical conditions and treatment 
efficacy. However, there is also a substantial body of research 
in which utilities were used to quantify preferences for treat-
ment attributes that could have an impact on convenience and 
quality of life. For example, previous studies have found that 
utilities differ depending on a range of treatment modalities, 
including surgical vs nonsurgical management;14 inhaled 
vs injected insulin;15 oral vs injectable treatment;16−18 dose 
frequency;19,20 inpatient vs outpatient treatment;21 two types 
of prenatal genetic testing;22 daily aspirin use;23 early-stage 
cervical cancer treatment options;24 and specific medication 
options.25 Across these studies, more convenient treatments 
were consistently associated with greater utility values.
Previous studies have found differences in patient prefer-
ence associated with SC injections and IV infusions for the 
treatment of a range of medical conditions.26−28 Therefore, it 
may be important to quantify the potential utility differences 
between injections and infusions in the context of treatment 
for patients with bone metastases in order to accurately 
represent these treatments in cost−effectiveness modeling. 
The purpose of the current study was to identify the impact 
of injection or infusion procedures on health state utility in 
the context of cancer with bone metastases. This study used 
time trade-off (TTO) interviews with general population 
 respondents in the UK to focus on the utility or disutility 
associated with each treatment modality, regardless of treat-
ment efficacy, adverse events, or other treatment outcomes.
Methods
Development of health states
The health state vignettes representing cancer with bone 
metastases and the addition of treatment modalities were 
drafted based on a literature review and interviews with 
clinicians. First, a literature review was conducted to iden-
tify articles on bone metastases and treatment of SREs to 
ensure that the health states would be grounded in clinical 
research.1−7 The information obtained from this literature 
search was used to draft structured interview guides for the 
clinician interviews.
Telephone interviews were conducted with four clinicians 
with MD degrees who specialized in oncology. One of these 
clinicians worked full time in clinical research, focusing on 
the treatment of patients with bone metastases. The other 
three clinicians were oncologists who primarily worked in 
clinical settings, treating patients with bone metastases while 
participating in clinical research. Each of the four clinicians 
participated in two telephone interviews before the health 
states were drafted. During these interviews, they responded 
to questions regarding administration procedures for deno-
sumab via SC injection and bisphosphonates via IV infusion, 
either alone or concomitant with chemotherapy. Each clini-
cian described their observations of patients’ experiences 
receiving these treatments as well as the language they use 
with patients to describe the administration procedures. 
Although denosumab was not publicly available at the time 
the study was conducted, all four clinicians had experience 
with this new treatment. The clinician who worked full 
time in clinical research had participated in several studies 
of denosumab, while the other three clinicians had direct 
experience treating patients with denosumab during clinical 
trials. The resulting descriptions were incorporated into draft 
health states.
Then, the four clinicians were interviewed again and 
asked to comment on how accurately and clearly the draft 
health states represented patients’ treatment experiences. In 
addition, the clinician who was based in the UK was asked 
to ensure that all language in the health states was appropri-
ate for UK respondents. The health states were edited until 
all clinicians agreed that they adequately represented the 
administration procedures for the relevant treatments.
After the health states were drafted, they were tested 
in a pilot study conducted with 20 members of the general 
London population (13 women; mean age = 32.4 years; age 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
856
Matza et al
Patient Preference and Adherence 2013:7
range = 21 to 50). The draft health states were administered 
in a TTO interview to ensure that respondents were able to 
understand the health states and the interview task. The par-
ticipants generally reported that the health states were clear 
and easy to understand. Some participants suggested minor 
revisions in formatting, phrasing, and explanation of the TTO 
task, and the health states were edited accordingly.
Final health states administered  
in the time trade-off interview
The final set of health state vignettes included a “basic health 
state (health state A),” which was designed to represent a 
patient with cancer and bone metastases but without descrip-
tion of a treatment. This health state included the following 
statements:
You have cancer that has spread to your bone. In parts of 
your body where the cancer has spread, the cancer can 
weaken your bones. You have pain where the cancer has 
spread to the bone. This pain is aching and present most 
of the time. The pain increases with movement, and it may 
interfere with your daily activities.
These statements had been used in a previous study 
designed to assess the health state utilities associated with 
bone metastases and SREs.29 In the TTO task, respondents 
considered living in this health state for a period of 2 years.
An additional nine health states (health states B to J) 
began with this basic health state, followed by additional 
statements describing a treatment involving either injec-
tion or infusion, in some cases combined with either renal 
monitoring or chemotherapy. The purpose of this study was 
to assess preferences for the various treatment modalities, 
independently of possible differences in treatment efficacy. 
Therefore, participants were explicitly told that there were 
no differences in the medical condition among the hypo-
thetical patients described in the health state vignettes. 
Interviewers provided the following instructions to the 
participants:
Please do not concern yourself with the effectiveness of 
the treatment. In all of these health states, you live for two 
years, and your cancer symptoms are the same. So just try 
to think about how you would feel about living in each 
health state for two years, while receiving the treatment as 
described. The key question is whether the experience of 
receiving these treatments changes the way you feel about 
living in health state A. In all health states, your condition 
remains unchanged for the two-year period.
Health state B included four statements designed to 
 represent injection procedures for denosumab.9,10,12,30
You are receiving treatment to stop your bones from becom-
ing weaker and to keep your bone pain from becoming 
worse. This treatment is a single injection, in which a needle 
is inserted just under the skin (ie, subcutaneous tissue), in 
the upper arm, lasting for less than 10 seconds. You may 
receive this treatment in a hospital outpatient clinic or at 
your doctor’s practice. You receive this treatment once 
every four weeks.
Health state C included four statements describing admin-
istration procedures for zoledronic acid, a commonly used 
bisphosphonate.31−33
You are receiving treatment to stop your bones from becom-
ing weaker and to keep your bone pain from becoming 
worse. This treatment is given by intravenous (IV) infusion, 
which means it is administered directly into the bloodstream 
through a tiny plastic tube inserted directly into a vein. It 
takes at least 30 minutes for the administration process. 
You receive this treatment at a hospital outpatient clinic in 
an IV treatment room where other patients may be receiv-
ing chemotherapy. You receive this treatment once every 
four weeks.
In health state C, the infusion process was indicated to 
last at least 30 minutes in order to represent the relatively 
short infusion time required for zoledronic acid. Infusions of 
zoledronic acid are recommended to occur over no less than 
15 minutes.8,32 However, actual times for the entire infusion 
process have been reported to last somewhat longer, ranging 
from 13 to 54 minutes.34,35 The four clinicians interviewed 
for the current study diverged on their description of the 
typical infusion duration, but all agreed that 30 minutes 
was a reasonable rough estimate. Health state D was identi-
cal to health state C, except for the duration of the infusion 
 process. In health state D, the infusion process was described 
as lasting 2 hours in order to represent a typical infusion time 
for pamidronate, another commonly used bisphosphonate, 
requiring infusion over a longer period of time.34,36
During the telephone interviews, the four clinicians 
agreed with published literature suggesting that blood draws 
were required for renal monitoring prior to the administration 
of bisphosphonates.8,37 However, opinions varied on whether 
blood draws occurred more commonly on the same day as 
the bisphosphonate infusion or on days prior to the bisphos-
phonate infusion. Therefore, two health states, E and F, were 
designed to represent these two renal monitoring approaches. 
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Health state E was the same as health state C (ie, zoledronic 
acid), with the addition of statements describing a blood draw 
on the same day as bisphosphonate treatment:
As part of your treatment plan, you have blood drawn so 
that your kidney function can be checked to make sure the 
treatment can be given (each time, the results of the blood 
draw indicate that you can receive the treatment). This blood 
draw is done before each IV treatment, and you have to wait 
two hours for results of the blood draw before receiving the 
IV treatment.
Similarly, health state F was the same as health state C, 
except for the addition of statements describing a blood draw 
2 days prior to bisphosphonate treatment:
As part of your treatment plan, you have blood drawn so 
that your kidney function can be checked to make sure the 
treatment can be given (each time, the results of the blood 
draw indicate that you can receive the treatment). This blood 
draw is done two days before receiving each IV treatment, 
as a separate appointment at the hospital outpatient clinic.
Health state G described chemotherapy. There are a wide 
range of chemotherapy administration procedures used in 
patients with solid tumors that tend to metastasize to bone.38−40 
Therefore, the four clinicians were questioned multiple times 
about the details of chemotherapy administration, including 
duration, frequency, location of IV infusion, and whether 
chemotherapy and bisphosphonate treatment could be coor-
dinated to be administered during the same appointment. 
The statements in the chemotherapy health states are based 
on a consensus from the four clinicians regarding a typical 
administration approach:
You require chemotherapy to stop the cancer from getting 
worse, which may have side effects such as hair loss, nausea, 
and fatigue. The chemotherapy treatment is administered 
into your bloodstream through an intravenous (IV) infusion, 
which lasts approximately 1.5 hours. You receive the che-
motherapy at a hospital outpatient clinic in an IV treatment 
room where other patients may be receiving chemotherapy. 
You receive the chemotherapy once every four weeks.
The final three health states (H, I, and J) were designed 
to identify differences in preference among the treatments 
associated with bone metastases when they were combined 
with chemotherapy. Each of these three health states included 
the chemotherapy statements from health state G. In addition, 
health state H included the injectable treatment described 
in health state B, while health states I and J included the 
 infusions described in health states C and D, respectively. 
Health states H, I, and J specify that the treatment asso-
ciated with bone metastases was administered after the 
chemotherapy.
The health state used as an upper anchor described a per-
son in full health with no cancer or any other health problems. 
A “death” health state was used as a lower anchor.
Participants
All participants were required to be (1) at least 18 years old; 
(2) able to understand the assessment procedures; (3) able 
and willing to give written informed consent; and (4) resid-
ing in the United Kingdom. Patients were not eligible if they 
had cognitive impairment, hearing difficulty, visual impair-
ment, severe psychopathology, or insufficient knowledge 
of English that could interfere with the ability to complete 
study measures. The TTO interviews were intended to yield 
utilities that may be used in submissions to agencies like 
National Institute for Health and Care Excellence (NICE), 
most of whom prefer that utilities represent general popula-
tion values.41−43 Therefore, the participant inclusion criteria 
did not specify any particular clinical characteristics.
Participants were recruited through newspaper and online 
advertisements in Edinburgh and London in July and August 
of 2011. A total of 462 potential participants responded to the 
newspaper advertisements by leaving a telephone message, 
and 225 of these were reached for screening to assess whether 
they met study inclusion criteria. All 225 potential partici-
pants were eligible, and 134 were able to be scheduled for 
interviews on the days the study was being conducted. A total 
of 126 participants attended interviews, and 121 of these 
participants were able to complete the TTO interview.
Utility interview procedures and scoring
The health states were presented during an interview follow-
ing a standardized interview script. There were two parts to 
this interview: First, participants rated the health states using 
a visual analog scale (VAS) that was intended to introduce 
participants to the content of the health states. Health states 
were presented on individual cards to each participant, and 
the ratings were relative to the anchor states of zero (death) 
and 100 (full health).
After participants completed the introductory VAS rat-
ing task, health state utilities were obtained using the TTO 
method, which has previously been described in detail.44 
TTO assessments of health state utilities are often conducted 
using a 10-year time horizon, as this time horizon was used 
in the Measurement and Valuation of Health study to elicit 
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 valuations from the general public for EQ-5D™ health 
states.45 However, other time horizons may be used, depend-
ing on what is most appropriate for the medical condition 
under examination. Similar to a previous study assessing 
health state utilities associated with bone metastases,29 the 
TTO task in the current study used a 2-year time horizon so 
that the impact of the bone treatment modalities would be 
judged within the context of a realistic life expectancy for a 
patient with advanced cancer and bone metastases.46
In the TTO task, participants were first presented with 
the basic health state (health state A) and offered a choice 
between spending 2 years in this health state versus spending 
varying shorter amounts of time in the full health state, fol-
lowed by death. After rating health state A, participants rated 
each of the other health states (health states B−J), in random 
order, following the same procedures. Participants concluded 
the TTO task by rating their own current health state.
For each health state rated as preferable to being dead 
in the TTO task, the utility value was calculated based on 
the choice in which the respondent is indifferent between y 
months in the health state being evaluated and x months in 
full health (followed by y − x months dead).47 The resulting 
utility estimate (u) is calculated as
 u = x/y. (1)
In the current study, y is 2 years. If participants indicated 
that a health state was worse than death, the interviewer altered 
the task so that respondents were offered a choice between 
immediate death (alternative 1) and a 2-year life span (alterna-
tive 2) beginning with varying amounts of time in the health 
state being rated, followed by full health for the remainder of 
the 2-year time horizon. For the TTO ratings of health states 
considered worse than being dead, the current study used a 
bounded scoring approach, which is commonly used to avoid 
highly skewed distributions.44 This scoring approach limits 
the score range of health states worse than death to between 
0 and −1. To compute these bounded negative utility values, 
the current study used the Dolan45 method as described by 
Rowen and Brazier.47 This method uses the formula
 u = −x/t, (2)
where x is the number of months in full health, and t is the 
total life span of alternative 2 in the TTO choice. In the cur-
rent study, t was 24 months, which is the number of months 
in the health state being rated plus subsequent months in 
full health.
The primary purpose of this study was to identify the 
disutility associated with each type of treatment modality. 
These disutilities were calculated as the difference between 
the utility of the basic health state (health state A: metastatic 
cancer without a treatment modality) and the utility of the 
otherwise identical health states with an added treatment 
modality. The calculation of the differences between health 
states to identify the disutilities of specific attributes has 
been shown to be useful in other disease areas, such as 
diabetes.19,48
Data collection and statistical analysis 
procedures
The one-on-one interviews were conducted in-person in 
private conference rooms in Edinburgh and London  during 
August 2011. All procedures and instruments were approved 
by an independent Institutional Review Board (Ethical and 
Independent Review Services, Corte Madera, CA, USA), 
and all participants provided written informed consent prior 
to completing any study measures. Statistical analyses were 
completed using SAS version 8.12 (SAS Institute Inc., Cary, 
NC, USA).
Continuous variables including utilities are summarized 
in terms of means and standard deviations, and categorical 
variables such as gender and race are summarized as frequen-
cies and percentages. The disutility (ie, utility shift) associated 
with each treatment modality was calculated by subtracting 
the utility of each treatment health state (B−J) from the utility 
of health state A. This disutility quantifies the impact of each 
treatment modality on preferences for health states in the 
context of cancer with bone metastases. A series of indepen-
dent t-tests (for continuous variables) and chi-square analyses 
(for categorical variables) were conducted to compare TTO 
utilities, utility shifts, and demographic characteristics of the 
samples from London (n = 57) and Edinburgh (n = 64), the 
two cities where data were collected.
Pairwise comparisons between health states, using 
t-tests, were conducted to examine differences in prefer-
ence for health states differing in treatment modality. The 
basic health state (health state A) was compared to each 
health state that included description of a treatment modality 
(health states B–J). Additional pairwise comparisons were 
performed to assess differences between the various types 
of treatments: injection (health state B) vs infusion (C, D); 
30-minute infusion (C) vs 2-hour infusion (D); 30-minute 
infusion (C) vs 30-minute infusion with renal monitoring 
(E, F); and injection (H) versus infusion (I, J) in the context 
of chemotherapy.
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Results
Sample description
The analysis sample includes 121 participants who were 
able to complete the utility interview (Table 1). The sample 
had a mean age of 40.8 years (SD = 13.8) and was 52.1% 
female. Most of the participants reported their ethnicity as 
white (76.9%), and the majority were employed either full 
time or part time (38.8% full time and 31.4% part time). More 
participants reported being single (n = 69 [57.0%]) than mar-
ried (n = 36 [29.8%]). Approximately half of the sample had 
completed a college or university degree (n = 60 [49.6%]). 
When asked to report health conditions, 44.6% of the sample 
reported none (n = 54). The most commonly reported health 
conditions were depression (n = 29 [24.0%]), hypertension 
(n = 9 [7.4%]), and arthritis (n = 8 [6.6%]). Only three par-
ticipants (2.5%) reported that they had a diagnosis of cancer 
at any time in their lives, and no participants reported cancer 
that had metastasized to the bone.
There were no significant differences between the London 
(n = 57) and Edinburgh (n = 64) samples in age, gender, mari-
tal status, employment status, or education level. The only 
statistically significant difference between the two geographic 
subsamples was in ethnicity (P , 0.001). The Edinburgh 
sample had a higher percentage of white participants than the 
London sample (92.2% vs 76.9%). In London, eight (14.0%) 
participants were black, 11 (19.3%) were Asian, and four 
(7.0%) reported their ethnicity as “other.” In Edinburgh, one 
(1.6%) participant was black, three (4.7%) were Asian, and 
one (1.6%) reported ethnicity as “other.”
Descriptive statistics: VAS ratings  
and health state utilities
The VAS scores and TTO utilities for all health states are 
presented in Table 2. In the total sample, the basic health state 
(A) describing cancer with bone metastases without treatment 
had a mean VAS score of 38.8 and a mean TTO utility of 0.40. 
Among the nine health states that included a treatment modal-
ity (health states B−J), the mean VAS scores ranged from 9.1 
to 38.2, and mean TTO utilities ranged from 0.19 to 0.39. The 
respondents’ mean ratings of their own current health were 
85.5 on the VAS and 0.92 in the TTO task, which reflects a 
general population sample in relatively good health.
The disutility associated with each treatment modality 
was computed by subtracting the utility of each health state 
describing a treatment from the utility of health state A, 
which is an otherwise identical health state without the 
inconveniences of a treatment modality (Table 2). Among 
the health states that did not include chemotherapy, the mean 
disutilities ranged from −0.004 for a monthly injection to 
−0.066 for monthly, 30-minute infusion plus renal monitor-
ing with a blood draw required 2 days prior to the infusion. 
The health states involving chemotherapy were associated 
with substantially greater mean disutilities, ranging from 
−0.175 for chemotherapy alone to −0.211 for chemotherapy 
in combination with an additional 2-hour infusion.
A series of t-tests was conducted to compare utilities 
and disutilities between the London (n = 57) and Edinburgh 
(n = 64) subsamples. For all health states, the Edinburgh 
sample had higher utility values than the London sample. The 
differences between the utilities of the two samples ranged 
from 0.08 to 0.17 across the ten health states. These differ-
ences were statistically significant for three health states (C, D, 
and F) (P , 0.05). However, the pattern of utilities indicating 
relative preferences among the health states was identical for 
the two geographic subsamples. Furthermore, there were no 
significant differences in the disutilities between the London 
and Edinburgh samples (P = 0.13 to 0.58). The differences 
between the two samples in the disutility associated with each 
treatment modality were minimal, with differences ranging 
from 0.01 (health states B and E) to 0.07 (I and J).
Table 1 Demographic characteristics
Characteristics Descriptive 
statistics (n = 121)
Age (mean, SD) 40.8 (13.8)
gender (n, %)
 Male 58 (47.9%)
 Female 63 (52.1%)
Ethnicity (n, %)
 White 93 (76.9%)
 Black 9 (7.4%)
 Asian 14 (11.6%)
 Other 5 (4.1%)
Marital status (n, %)
 Single 69 (57.0%)
 Married 36 (29.8%)
 Living with partner 4 (3.3%)
 Divorced/separated 12 (9.9%)
Employment status (n, %)
 Full-time work 47 (38.8%)
 Part-time work 38 (31.4%)
 Unemployed 11 (9.1%)
 Other* 25 (20.7%)
Education level (n, %)
 Completed college or university degree 60 (49.6%)
 Did not complete college or university degree 61 (50.4%)
Location
 Edinburgh 64 (52.9%)
 London 57 (47.1%)
Note: *“Other” includes student, homemaker, retired, and disabled.
Abbreviation: SD, standard deviation.
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Comparisons among health state utilities
Paired t-tests were conducted to examine whether the dif-
ferences among the health state utilities were statistically 
significant. The difference between health states A and B 
was not statistically significant (P = 0.25). The utilities of 
all the other health states with treatment modalities (C−J) 
were significantly different from the utility of the basic health 
state without a treatment modality (t = 2.8 to 9.3) (P = 0.006 
[A vs C]; P , 0.001 [all other comparisons]).
Paired t-tests were also conducted to examine whether 
the utilities of health states differing by a single treatment 
attribute were significantly different from each other (Table 3). 
All differences were statistically significant. For example, 
the health state describing an injection (health state B) was 
associated with a significantly higher utility than the health 
states representing the 30-minute infusion (P = 0.01) and the 
2-hour infusion (P , 0.001). Adding renal monitoring to the 
30-minute infusion resulted in a significantly lower utility 
(P , 0.001) than the 30-minute infusion alone, regardless 
of whether renal monitoring occurred on the same day as the 
infusion (E) or 2 days prior to the infusion (F). There were also 
significant differences between the 30-minute infusion (C) and 
the 2-hour infusion (D) (P = 0.002), as well as between the 
two types of renal monitoring (E vs F) (P = 0.005).
The differences among the treatment modalities were 
also statistically significant when presented in combination 
with chemotherapy (Table 3). The health state representing 
an injection plus chemotherapy (H) had a significantly lower 
utility than the health state representing chemotherapy alone 
(G) (P = 0.004). However, the injection health state with 
chemotherapy had a significantly higher utility than either 
the 30-minute or 2-hour infusion health states (I and J) 
(both P , 0.01). These two health states representing infu-
sion plus chemotherapy, which differed only by the duration 
of infusion, were significantly different from each other 
(P = 0.003).
Discussion
The results of this study indicate that treatment modality had 
an impact on preference and utility, independently of treat-
ment effectiveness or tolerability. Although this is the first 
study assessing utility associated with the characteristics of 
treatment for patients with bone metastases, the findings are 
consistent with results of studies in other disease areas report-
ing that more convenient treatments tend to be associated 
with greater utility.15−17,19,21,22 During the interviews conducted 
for the current study, respondents often commented on the 
importance of treatment convenience in the context of the 
bone metastases health states, particularly when consider-
ing the impact of more intensive, time-consuming medical 
procedures.
The utility differences between SC injection and IV 
infusion were relatively small, ranging from roughly 0.01 
to 0.03, depending on the infusion duration and presence 
of chemotherapy. In comparison, health states representing 
different levels of symptom severity have repeatedly been 
found to have utility differences of at least 0.10.49−51 However, 
the current differences between injection and infusion may 
still be important because small differences in utility can 
have a substantial impact on the outcomes of a cost−utility 
Table 2 Health state VAS ratings and time trade-off utilities
Health states VAS ratings 
(n = 121) 
mean (SD)
Time trade-off utilities
Health state utility 
(n = 121) 
mean (SD)
Disutility of 
each treatment 
modality*
A:  Basic health state (cancer with bone metastases, no treatment) 38.8 (19.1) 0.40 (0.43) –
B:  Injection 38.2 (17.4) 0.39 (0.43) −0.004 (0.036)
C:  30-minute infusion 33.1 (17.0) 0.38 (0.44) −0.023 (0.090)
D:  2-hour infusion 28.0 (17.2) 0.36 (0.44) −0.037 (0.106)
E:  30-minute infusion + renal monitoring (blood draw on same day as infusion) 25.7 (18.0) 0.35 (0.43) −0.050 (0.124)
F:  30-minute infusion + renal monitoring (blood draw 2 days prior to infusion) 22.1 (16.9) 0.33 (0.44) −0.066 (0.122)
g:  Chemotherapy 17.1 (17.4) 0.22 (0.46) −0.175 (0.225)
H:  Injection + chemotherapy 14.1 (17.4) 0.21 (0.46) −0.190 (0.231)
I:  30-minute infusion + chemotherapy 11.6 (17.6) 0.20 (0.46) −0.202 (0.239)
J:  2-hour infusion + chemotherapy 9.1 (17.9) 0.19 (0.46) −0.211 (0.248)
Own current health state 85.5 (14.7) 0.92 (0.12) –
Notes: *This difference score represents the impact of adding each treatment modality to an otherwise identical health state. These values can be interpreted as the 
“disutility” or utility shift associated with each treatment modality. For health states B to J, the disutility is computed by subtracting the utility of health state A from the utility 
of each other health state. A negative utility shift indicates that the health state was rated lower than health state A.
Abbreviations: SD, standard deviation; VAS, visual analog scale.
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analysis when modeling a large number of patients over 
years of treatment.
The differences among the health state utilities followed 
logical patterns, indicating that participants understood the 
health states and the TTO task. Of all the treatment approaches 
represented in the health states, a monthly SC injection had 
the smallest impact on utility (−0.004 without chemotherapy 
and −0.015 in the context of chemotherapy). The great 
majority (n = 103 [85.1%]) of the 121 participants did not 
differentiate between health states A (no treatment modal-
ity) and B (with the injection) in the TTO task, indicating 
that the injection did not have a significant impact on health 
state preference. Among the 18 (14.9%) who did differentiate 
between these two health states, 12 (9.9%) preferred health 
state A because they preferred to avoid the inconvenience 
of the treatment. The other six respondents (5.0%) preferred 
health state B because they thought the treatment would be 
of psychological benefit, even if there was no difference 
between the two health states in symptoms or health 
status.
Both the 30-minute and 2-hour IV infusions were asso-
ciated with significantly greater disutility than SC injection 
(Table 3). Although the magnitude of the differences between 
the injection and infusion health state utilities tended to be 
small, they did reach statistical significance. Of the 121 
respondents, 20 (16.5%) differentiated between health states 
B (injection) and C (30-minute infusion), resulting in a util-
ity difference of −0.019 between the two health states. Each 
additional inconvenience added to the infusion procedure 
led to an increased disutility. These inconveniences included 
a longer infusion process (health state D), a blood draw for 
renal monitoring occurring on the same day as the infusion 
(E), and a blood draw occurring 2 days prior to the infu-
sion (F). Overall, this pattern of results suggests that small 
Table 3 Results of t-tests comparing pairs of health states
Comparison Health states Mean (SD) Difference score t-value (paired) P-value
Health states without chemotherapy
B vs C B:  Injection 0.39 (0.43) 0.019 2.6 0.0106
C:  30-minute infusion 0.38 (0.44)
B vs D B:  Injection 0.39 (0.43) 0.033 3.8 0.0002
D:  2-hour infusion 0.36 (0.44)
C vs D C:  30-minute infusion 0.38 (0.44) 0.013 3.1 0.0024
D:  2-hour infusion 0.36 (0.44)
C vs E C:  30-minute infusion 0.38 (0.44) 0.026 4.1 ,0.0001
E:  30-minute infusion + renal monitoring  
(blood draw on same day as infusion)
0.35 (0.43)
C vs F C:  30-minute infusion 0.38 (0.44) 0.043 5.6 ,0.0001
F:  30-minute infusion + renal monitoring  
(blood draw 2 days prior to infusion)
0.33 (0.44)
E vs F E:  30-minute infusion + renal monitoring  
(blood draw on same day as infusion)
0.35 (0.43) 0.017 2.9 0.0045
F:  30-minute infusion + renal monitoring  
(blood draw 2 days prior to infusion)
0.33 (0.44)
Health states with chemotherapy
g vs H g:  Chemotherapy 0.22 (0.46) 0.015 2.9 0.0041
H:  Injection + chemotherapy 0.21 (0.46)
g vs I g:  Chemotherapy 0.22 (0.46) 0.027 3.7 0.0003
I:  30-minute infusion + chemotherapy 0.20 (0.46)
g vs J g:  Chemotherapy 0.22 (0.46) 0.036 4.4 ,0.0001
J:  2-hour infusion + chemotherapy 0.19 (0.46)
H vs I H:  Injection + chemotherapy 0.21 (0.46) 0.012 3.2 0.0019
I:  30-minute infusion + chemotherapy 0.20 (0.46)
H vs J H:  Injection + chemotherapy 0.21 (0.46) 0.021 4.1 ,0.0001
J:  2-hour infusion + chemotherapy 0.19 (0.46)
I vs J I:  30-minute infusion + chemotherapy 0.20 (0.46) 0.009 3.1 0.0025
J:  2-hour infusion + chemotherapy 0.19 (0.46)
Abbreviation: SD, standard deviation.
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 differences in treatment convenience can have an impact on 
preference and health state utility.
Chemotherapy was associated with a much greater disutil-
ity than any of the treatments focused on bone metastases. 
Of the 121 respondents, 88 (72.7%) differentiated between 
the health states with and without chemotherapy (A vs G), 
resulting in a disutility of −0.17 for chemotherapy. Many of 
the respondents mentioned that their negative impression 
of chemotherapy was based not only on the health states 
themselves, but also on their observations of friends or fam-
ily members who had received this type of treatment. This 
finding highlights strengths and weaknesses of the current 
study design. For example, reimbursement authorities often 
prefer that utilities are derived from general population 
samples, such as the sample in the current study, to ensure 
that societal values are represented when making decisions 
about public funding for medical treatment.41–43 However, it is 
not known whether a sample of patients with direct relevant 
experience would report different preferences than a general 
population sample. With regard to the current health states, 
it is possible that patients who had been treated with che-
motherapy would be more or less accepting of its drawbacks 
than general population respondents who do not have direct 
experience with the treatment.
Like the use of the general population sample, vignette-
based utility assessment methods also have strengths and 
limitations. In studies using this methodology, respondents 
rate health states based on brief vignettes, rather than direct 
personal experience. Although the vignettes for the current 
study were carefully drafted based on published literature and 
clinician experience with the treatment modality, the validity 
of each utility is limited by the level of detail and accuracy of 
the descriptions of the treatments. For example, the vignettes 
for the current study described each treatment as occurring 
once per month. However, the actual frequency of bispho-
sphonate infusions in real-world settings may vary across 
settings and patients, with some patients receiving treatment 
as often as every 3 weeks.5 Greater treatment frequency would 
likely be associated with greater inconvenience, which could 
influence a utility value. Unfortunately, the current vignette-
based approach is unable to accurately capture this sort of 
variation among treatment experiences. Still, vignette-based 
utility assessment is often the best way to target the utilities 
of specific factors that may be difficult to isolate in a patient 
sample, such as the small differences in treatment modality, 
which were the focus of the current study. In contrast, generic 
instruments designed to derive utilities from patient samples, 
such as the EQ-5D45 or Health Utilities Index,52 may not have 
items or response options that are sensitive to such specific 
treatment attributes.53 The extent to which vignette-based 
utilities would correspond to utilities derived from direct 
patient experience is likely to vary depending on the medical 
condition and treatment in question.
The current findings show that treatment modality can 
have a significant effect on health state utility. The disutilities 
suggest that respondents perceived an inconvenience with 
each type of treatment for bone metastases, although SC 
injections were preferred over IV infusions, as indicated by 
the significant differences in mean utilities. The pattern of 
findings highlights the potential advantages of denosumab via 
SC injection in comparison with bisphosphonates, which are 
administered via intravenous infusions. The disutility associ-
ated with each treatment modality may be useful to include 
in cost−utility models estimating the value of treatments for 
patients with bone metastases.
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